Skin Cancer Treatment Options

• Treatment for skin cancer is chosen based on the specific type involved — basal cell carcinoma, squamous cell carcinoma, or melanoma — along with the tumor’s stage, size, and location and the patient’s overall health.
• Basal cell and squamous cell carcinoma are usually treated with surgery, most often simple excision or Mohs micrographic surgery, and are frequently cured when caught early.
• Non-surgical options for basal cell and squamous cell carcinoma — radiation therapy, topical medication, and photodynamic therapy — are standard choices for superficial disease or when surgery is not the best fit.
• Melanoma is treated differently: wide local excision is the primary surgery at every stage, and Mohs surgery is not the standard technique used for it.
• Advanced disease has its own systemic drugs by type — targeted therapy and immunotherapy for melanoma differ from the Hedgehog-pathway inhibitors and checkpoint drugs used for advanced basal and squamous cell carcinoma.

Understanding Skin Cancer Treatment Options

A skin cancer diagnosis opens up a set of treatment decisions, and which options actually apply depends heavily on which of the three common types is involved. In broad strokes, every approach tries to clear the cancerous cells while limiting damage to the surrounding skin — but basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are generally managed with a menu of surgical and skin-directed treatments, while melanoma care centers on surgical removal and, for more advanced disease, therapies that act throughout the body rather than only at the tumor site.

Factors Influencing Treatment Choice

Several variables steer the decision: which type of skin cancer is present, how advanced it is, the tumor’s size and where it sits on the body, and whether it has spread beyond the original site. A small, early basal cell carcinoma on the forearm and an aggressive melanoma on the face call for very different plans, even though both fall under the umbrella term “skin cancer.” A patient’s age, general health, other medical conditions, and personal priorities factor in as well, and care is often coordinated by more than one specialist — typically a dermatologist working alongside a surgical or medical oncologist.

Initial Diagnosis and Staging

Diagnosis starts with a biopsy: a sample of the suspicious lesion is removed and examined under a microscope to confirm the type of cancer present. For melanoma, staging goes further. According to the National Cancer Institute’s PDQ melanoma treatment summary, prognosis and treatment options are weighed against tumor thickness and location, whether the skin over the tumor has broken down (ulceration), how much cancer has reached the lymph nodes, how much of the blood enzyme LDH (lactate dehydrogenase) is present, and whether the tumor carries a mutation in the BRAF gene — a detail that later determines whether BRAF-targeted therapy is even an option. Basal cell and squamous cell carcinoma spread beyond the skin far less often, so their evaluation leans more on the tumor’s size, depth, and location than on lymph node testing, which is one reason the treatment menu for these cancers looks different from melanoma’s from the very first visit.

Surgical Skin Cancer Treatment Methods

Removing the tumor surgically is the backbone of treatment for localized skin cancer of any type, though which procedure is used — and how much tissue comes with it — depends on the type being treated. Basal cell and squamous cell carcinoma have several surgical options available, several of which can be curative on their own. Melanoma surgery, by contrast, follows a more standardized protocol built around removing the tumor with a defined margin of normal skin.

Excisional Surgery

For basal cell carcinoma and squamous cell carcinoma, the National Cancer Institute’s PDQ skin cancer treatment summary lists simple excision — cutting out the tumor with a rim of normal-looking skin around it — as one of several standard surgical options, alongside techniques such as curettage and electrodesiccation or cryosurgery. The removed tissue is then checked under a microscope to confirm the edges are free of cancer cells before the wound is closed.

Melanoma surgery works differently. Guidance on melanoma treatment describes wide local excision — taking the melanoma along with a margin of surrounding tissue — is the primary treatment at every stage, and skin grafting — using skin taken from elsewhere on the body — may be used to close the wound when a larger area is removed. Because melanoma can reach nearby lymph nodes even when the tumor on the skin looks small, the excision is often paired with lymph node mapping and a sentinel lymph node biopsy, which checks the first node the cancer would likely spread to. When only a trace amount of cancer turns up there, monitoring with ultrasound is sometimes used instead of removing further nodes.

Mohs Micrographic Surgery

Mohs micrographic surgery works layer by layer: a thin slice of the tumor is removed and examined under a microscope on the spot, and the surgeon keeps taking additional layers from wherever cancer cells are still seen until none remain. Because the mapping is this precise, more healthy tissue is spared than with a standard excision, which is why doctors commonly choose it for basal cell and squamous cell carcinoma in places where preserving tissue matters most — such as the face, the fingers, or the genital area — or where a tumor’s border is difficult to define.

Mohs surgery is not the standard approach for melanoma. Wide local excision — not the layer-by-layer, microscope-guided technique used for BCC and SCC — remains the surgery used across every stage of melanoma.

Non-Surgical Skin Cancer Treatments

When surgery is not the best fit — because a lesion is superficial, sits somewhere an operation would be difficult, or a patient’s health makes surgery risky — several non-surgical options exist. For basal cell and squamous cell carcinoma, these are largely skin-directed treatments applied at the site of the tumor. Melanoma’s non-surgical options work differently: apart from radiation used to relieve symptoms, non-surgical melanoma care generally means a therapy that acts throughout the body, which is covered under emerging and systemic therapies below.

Radiation Therapy

Radiation therapy directs high-energy x-rays at the tumor to destroy cancer cells or stop them from growing. Doctors turn to it for basal cell and squamous cell carcinoma, often when a tumor is large, sits somewhere surgery would be difficult, or a patient is not a good surgical candidate. In melanoma, radiation plays a narrower role, used mainly to relieve symptoms from disease that has reached the brain, the spinal cord, or the bones, rather than as a primary treatment for the original skin tumor.

Topical Treatments and Photodynamic Therapy

Topical treatment means applying medication directly to the skin rather than removing tissue. For these cancers, chemotherapy is usually given this way — topical fluorouracil, for example, is used on basal cell carcinoma — and topical imiquimod, which works by prompting the immune system to attack the abnormal cells, is used for some basal cell carcinomas as well. Actinic keratosis, the precancerous skin change that can progress into squamous cell carcinoma, has its own topical options, including diclofenac and ingenol, in addition to chemical peels and several of the surgical techniques described above.

Photodynamic therapy takes a different approach: a light-sensitizing drug is applied to the skin, and a specific wavelength of light then activates it to destroy the treated cells while sparing much of the surrounding healthy tissue. Photodynamic therapy is an option for actinic keratosis and, specifically, for squamous cell carcinoma in situ — the earliest, non-invasive stage of that cancer.

Emerging Therapies and Future Advancements

The treatments generating the most momentum right now work systemically, through the bloodstream or the immune system, rather than by cutting, freezing, or irradiating the tumor directly. That shift matters most for cancer that has spread beyond the original site or come back after earlier treatment — and, again, the specific drugs used differ by which skin cancer is being treated.

Targeted Therapy and Immunotherapy

Advanced melanoma has its own set of targeted therapy drugs, built around a specific genetic change. When a melanoma carries a mutation in the BRAF gene, BRAF inhibitors — dabrafenib, vemurafenib, or encorafenib — may be used, typically paired with a MEK inhibitor such as trametinib, cobimetinib, or binimetinib. Guidance on melanoma treatment also lists immunotherapy drugs used for melanoma, including pembrolizumab, nivolumab, ipilimumab, atezolizumab, interleukin-2, and the nivolumab-relatlimab combination, which may be given alone or together depending on the case. For melanoma that cannot be removed surgically, an additional option is oncolytic virus therapy, talimogene laherparepvec, which is injected directly into the tumor.

Basal and squamous cell carcinoma have a separate, smaller set of systemic drugs, reserved for disease that has spread beyond the skin or is otherwise out of reach for local treatment. For advanced basal cell carcinoma, targeted therapy uses signal transduction inhibitors — vismodegib or sonidegib — that block a growth-signaling pathway inside the cancer cells, while advanced squamous cell carcinoma may be treated with the immunotherapy drugs cemiplimab or pembrolizumab. These checkpoint drugs work by blocking the same PD-1/PD-L1 signal that immunotherapy blocks in melanoma, but they are approved for a different cancer, and the two drug lists are not interchangeable.

Clinical Trials and Research

Both the PDQ skin cancer and PDQ melanoma summaries note that additional treatments are continually being tested in clinical trials — research studies that compare a new approach against the current standard of care. Taking part can give patients access to treatments not yet widely available, and over time, this is how many of today’s standard treatments, including the targeted and immune therapies described above, became standard in the first place. Enrolling trials for skin cancer can be searched through ClinicalTrials.gov, the U.S. National Library of Medicine’s public trial registry, or through a dedicated cancer clinical trial search tool.

Frequently Asked Questions

What factors determine the best skin cancer treatment?

Several things shape which treatment path is considered for a given case: which of the three main types is involved (basal cell carcinoma, squamous cell carcinoma, or melanoma), how advanced the disease is, the tumor’s size and location, and patient-specific factors such as age, overall health, and personal preferences. For melanoma, tumor thickness, ulceration, lymph node involvement, and BRAF mutation status are weighed as well, since mutation status determines whether targeted therapy is an option at all. A dermatologist or oncologist reviews these factors together to narrow the choices, generally aiming to remove the cancer while preserving as much healthy tissue and function as possible.

Are non-surgical treatments as effective as surgery for skin cancer?

For basal cell carcinoma, squamous cell carcinoma in situ, and actinic keratosis — all of which tend to stay confined to the surface of the skin — guidance on this topic lists non-surgical options such as photodynamic therapy and topical medication as standard treatments in their own right, not merely as fallbacks. Melanoma is different: removing the tumor surgically is the standard of care at every stage of melanoma, and the systemic therapies described above are generally reserved for disease that surgery cannot fully clear or that has spread beyond the original site. Which approach fits a particular case is a decision made with a dermatologist or oncologist, based on the specific diagnosis.

What are the most significant recent advancements in skin cancer treatment?

The most notable recent progress has been in systemic therapy — treatment that works through the body rather than only at the tumor site — and it has developed somewhat separately for melanoma versus basal and squamous cell carcinoma. In melanoma, BRAF- and MEK-targeted drugs and checkpoint immunotherapy have measurably changed the outlook for advanced and metastatic disease. In basal and squamous cell carcinoma, the newer additions are the Hedgehog-pathway inhibitors used for advanced basal cell carcinoma and the checkpoint inhibitors approved for advanced squamous cell carcinoma. All of these remain systemic options for more advanced disease, rather than replacements for the surgical and skin-directed treatments that stay standard for most early-stage cases.

Sources

• National Cancer Institute – Skin Cancer Treatment (PDQ®) – Patient Version
• National Cancer Institute – Melanoma Treatment (PDQ®) – Patient Version
• National Cancer Institute – Skin Cancer (Including Melanoma)
• U.S. National Library of Medicine – ClinicalTrials.gov